Angiotensin II activates MCP-1 and induces cardiac hypertrophy and dysfunction via toll-like receptor 4

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 8, 2015, Pages 833-844

  Matsuda, Susumu ^a   Umemoto, Seiji ^b   Yoshimura, Koichi ^a   Itoh, Shinichi ^a   Murata, Tomoaki ^c   Fukai, Tohru ^d   Matsuzaki, Masunori ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

^c YAMAGUCHI UNIVERSITY   (Japan)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Angiotensin II; Cardiac hypertrophy; Hypertension; Monocyte chemoattractant protein 1; Mouse; Toll like receptor 4

Indexed keywords

ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRBESARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NORADRENALIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR 4; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE; VASOCONSTRICTOR AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR PARAMETERS; CELL INFILTRATION; ECHOCARDIOGRAPHY; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEFT VENTRICULAR WEIGHT; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; VASCULAR FIBROSIS; VASCULAR REMODELING; ANIMAL; BAGG ALBINO MOUSE; CARDIOMEGALY; HYPERTENSION; PHYSIOLOGY;

ADRENERGIC ALPHA-AGONISTS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; CARDIOMEGALY; CHEMOKINE CCL2; HYPERTENSION; MALE; MICE; MICE, INBRED BALB C; NOREPINEPHRINE; OXIDATIVE STRESS; TETRAZOLES; TOLL-LIKE RECEPTOR 4; VASOCONSTRICTOR AGENTS;

EID: 84940387844     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.27292     Document Type: Article

References (44)

1. Kurdi M, Booz GW: New take on the role of angiotensin Ⅱ in cardiac hypertrophy and fibrosis. Hypertension, 2011; 57: 1034-1038
2. Touyz RM, Briones AM: Reactive oxygen species and vascular biology: implications in human hypertension. Hypertens Res, 2011; 34: 5-14
3. Chinnaiyan KM, Alexander D, McCullough PA: Role of angiotensin Ⅱ in the evolution of diastolic heart failure. J Clin Hypertens (Greenwich), 2005; 7: 740-747
4. Kono M, Kisanuki A, Ueya N, Kubota K, Kuwahara E, Takasaki K, Yuasa T, Mizukami N, Miyata M, Tei C: Left ventricular global systolic dysfunction has a significant role in the development of diastolic heart failure in patients with systemic hypertension. Hypertens Res, 2010; 33: 1167-1173
5. Lalande S, Johnson BD: Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today (Barc), 2008; 44: 503-513
6. Li L, Zhou N, Gong H, Wu J, Lin L, Komuro I, Ge J, Zou Y: Comparison of angiotensin Ⅱ type 1-receptor blockers to regress pressure overload-induced cardiac hypertrophy in mice. Hypertens Res, 2010; 33: 1289-1297
7. Kumar H, Kawai T, Akira S: Pathogen recognition by the innate immune system. Int Rev Immunol, 2011; 30: 16-34
8. Mann DL: The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res, 2011; 108: 1133-1145
9. Ha T, Li Y, Hua F, Ma J, Gao X, Kelley J, Zhao A, Haddad GE, Williams DL, William Browder I, Kao RL, Li C: Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc Res, 2005; 68: 224-234
10. Eissler R, Schmaderer C, Rusai K, Kuhne L, Sollinger D, Lahmer T, Witzke O, Lutz J, Heemann U, Baumann M: Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res, 2011; 34: 551-558
11. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, Doevendans PA, van Echteld CJ, Joles JA, Quax PH, Piek JJ, Pasterkamp G, de Kleijn DP: Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res, 2008; 102: 257-264
12. Landmesser U, Wollert KC, Drexler H: Potential novel pharmacological therapies for myocardial remodelling. Cardiovasc Res, 2009; 81: 519-527
13. Sales ML, Schreiber R, Ferreira-Sae MC, Fernandes MN, Piveta C, Cipolli JA, Calixto A, Matos-Souza JR, Geloneze B, Franchini KG, Nadruz W Jr: The functional Toll-like receptor 4 Asp299Gly polymorphism is associated with lower left ventricular mass in hypertensive women. Clin Chim Acta, 2010; 411: 744-748
14. Sales ML, Schreiber R, Ferreira-Sae MC, Fernandes MN, Piveta CS, Cipolli JA, Cardoso CC, Matos-Souza JR, Geloneze B, Franchini KG, Nadruz W Jr: Toll-like receptor 6 Ser249Pro polymorphism is associated with lower left ventricular wall thickness and inflammatory response in hypertensive women. Am J Hypertens, 2010; 23: 649-654
15. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM: Inflammation, immunity, and hypertension. Hypertension, 2011; 57: 132-140
16. Eißler R, Schmaderer C, Rusai K, Kühne L, Sollinger D, Lahmer T, Witzke O, Lutz J, Heemann U, Baumann M: Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res, 2011; 34: 551-555
17. Iwai M, Mogi M, Horiuchi M: Role of NAD(P)H oxidase and its regulation in chronic hypertension. Hypertens Res, 2006; 29: 743-744
18. Lemarie CA, Schiffrin EL: The angiotensin Ⅱ type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst, 2010; 11: 19-31
19. Brasier AR: The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res, 2010; 86: 211-218
20. Vogel SN, Wax JS, Perera PY, Padlan C, Potter M, Mock BA: Construction of a BALB/c congenic mouse, C.C3HLpsd, that expresses the Lpsd allele: analysis of chromosome 4 markers surrounding the Lps gene. Infect Immun, 1994; 62: 4454-4459
21. Poltorak A, He X, Smirnova I, Liu M-Y, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B: Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene. Science, 1998; 282: 2085-2088
22. Zhou YQ, Zhu Y, Bishop J, Davidson L, Henkelman RM, Bruneau BG, Foster FS: Abnormal cardiac inflow patterns during postnatal development in a mouse model of Holt-Oram syndrome. Am J Physiol Heart Circ Physiol, 2005; 289: H992-H1001
23. Yamada M, Ikeda Y, Yano M, Yoshimura K, Nishino S, Aoyama H, Wang L, Aoki H, Matsuzaki M: Inhibition of protein phosphatase 1 by inhibitor-2 gene delivery ameliorates heart failure progression in genetic cardiomyopathy. FASEB J, 2006; 20: 1197-1199
24. Umeji K, Umemoto S, Itoh S, Tanaka M, Kawahara S, Fukai T, Matsuzaki M: Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. Am J Physiol Heart Circ Physiol, 2006; 291: H2522-2532
25. Hashimoto R, Umemoto S, Guo F, Umeji K, Itoh S, Kishi H, Kobayashi S, Matsuzaki M: Nifedipine activates PPARgamma and exerts antioxidative action through Cu/ ZnSOD independent of blood-pressure lowering in SHRSP. J Atheroscler Thromb, 2010; 17: 785-795
26. Kawahara S, Umemoto S, Tanaka M, Umeji K, Matsuda S, Kubo M, Matsuzaki M: Up-regulation of Akt and eNOS induces vascular smooth muscle cell differentiation in hypertension in vivo. J Cardiovasc Pharmacol, 2005; 45: 367-374
27. Itoh S, Umemoto S, Hiromoto M, Toma Y, Tomochika Y, Aoyagi S, Tanaka M, Fujii T, Matsuzaki M: Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. Circulation, 2002; 105: 2288-2295
28. Kubo M, Umemoto S, Fujii K, Itoh S, Tanaka M, Kawahara S, Matsuzaki M: Effects of angiotensin Ⅱ type 1 receptor antagonist on smooth muscle cell phenotype in intramyocardial arteries from spontaneously hypertensive rats. Hypertens Res, 2004; 27: 685-693
29. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M: Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med, 2005; 11: 1330-1338
30. Wollert KC, Drexler H: The renin-angiotensin system and experimental heart failure. Cardiovasc Res, 1999; 43: 838-849
31. Ohashi K, Burkart V, Flohe S, Kolb H: Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol, 2000; 164: 558-561
32. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF, 3rd: The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem, 2001; 276: 10229-10233
33. Dange RB, Agarwal D, Masson GS, Vila J, Wilson B, Nair A, Francis J: Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin Ⅱ-induced hypertension. Cardiovasc Res, 2014; 103: 17-27
34. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, Conway SJ, Nagai R: Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure over-load. J Clin Invest, 2010; 120: 254-265
35. Paravicini TM, Touyz RM: Redox signaling in hypertension. Cardiovasc Res, 2006; 71: 247-258
36. Vogel V, Bokemeyer D, Heller J, Kramer HJ: Cardiac hypertrophy in the Prague-hypertensive rat is associated with enhanced JNK2 but not ERK tissue activity. Kidney Blood Press Res, 2001; 24: 52-56
37. Valen G: Innate immunity and remodelling. Heart Fail Rev, 2011; 16: 71-78
38. Kamioka M, Ishibashi T, Sugimoto K, Uekita H, Nagai R, Sakamoto N, Ando K, Ohkawara H, Teramoto T, Maruyama Y, Takeishi Y: Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J Atheroscler Thromb, 2010; 17: 590-600
39. Yang J, Jiang H, Ding JW, Chen LH, Li S, Zhang XD: Valsartan preconditioning protects against myocardial ischemia- reperfusion injury through TLR4/NF-kappaB signaling pathway. Mol Cell Biochem, 2009; 330: 39-46
40. Anrather J, Racchumi G, Iadecola C: NF-kappaB regulates phagocytic NADPH oxidase by inducing the expression of gp91phox. J Biol Chem, 2006; 281: 5657-5667
41. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP: Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor gamma coactivator- 1 signaling. Circ Heart Fail, 2011; 4: 474-482
42. Wang Y, Li Y, Wu Y, Jia L, Wang J, Xie B, Hui M, Du J: 5TNF-alpha and IL-1beta neutralization ameliorates angiotensin Ⅱ-induced cardiac damage in male mice. Endocrinology, 2014; 155: 2677-2687
43. Ceyhan C, Unal S, Yenisey C, Tekten T, Ceyhan FB: The role of N terminal pro-brain natriuretic peptide in the evaluation of left ventricular diastolic dysfunction: correlation with echocardiographic indexes in hypertensive patients. Int J Cardiovasc Imaging, 2008; 24: 253-259
44. Parker LC, Whyte MKB, Vogel SN, Dower SK, Sabroe I: Toll-like receptor (TLR)2 and TLR4 agonists regulate CCR expression in human monocytic cells. J Immunol, 2004; 172: 4977-4986